angiogenesis inhibitors

Aflibercept - Bevacizumab - Cediranib - Motesanib - Sorafenib - Vandetanib      

Select            
Trial Studied trt Control trt patientstagsROB Trial result

advanced breast cancer (metastatic)

bevacizumab
RIBBON-I (Robert) on top capecitabine, 2009     bevacizumab + capecitabinecapecitabine 1st line Low risk of bias negative
AVF2119g (Miller) cape, 2005   bevacizumab + capecitabinecapecitabine 2nd line Risk of bias negative
RIBBON-2 (Brufsky), 2009     bevacizumav + CTCT alone 2nd line negative
AVADO (Miles) 15mg , 2009     bevacizumab + docetaxeldocetaxel 1st line HER-2 negative suggesting
AVADO (Miles) 7.5mg, 2010   bevacizumab + docetaxeldocetaxel 1st line HER-2 negative Low risk of bias -
Burstein, 2005   bevacizumab + methotrexatemethotrexate -
Martin bevacizumab, 2011     bevacizumab + paclitaxelpaclitaxel 1st line HER-2 negative Risk of bias -
E2100 (Miller), 2007      NCTbevacizumab + taxanestaxanes 1st line Risk of bias negative
RIBBON-I (Robert) on top Tax or anthra, 2009     bevacizumab + taxanestaxanes 1st line -
ceritinib
Hyams      NCTcediranib + fulvestrantfulvestrant -
motesanib
Martin (motesanib), 2011      NCTmotesanib + paclitaxelpaclitaxel 1st line HER-2 negative Low risk of bias -
sorafenib
Schwartzberg, 2013      NCTsorafenib + gemcitabine or capecitabinegemcitabine or capecitabine alone 2nd line HER-2 negative Exploratory -
Gradishar, 2013     sorafenib + paclitaxelpaclitaxel alone 1st line HER-2 negative Low risk of bias -

lung cancer (metastatic)

aflibercept
Ramlau, 2012     Aflibercept and Docetaxel Docetaxel Low risk of bias -
bevacizumab
Reck, 2010     bevacizumab -
Herbst, 2011     bevacizumab + erlotiniberlotinib alone -
Sandler, 2006     bevacizumabplatinum based CT -
Johnson, 2004     bevacizumabplatinum based CT -
Nishio, 2009   bevacizumabplatinum based CT -
Herbst, 2007     bevacizumabplatinum based CT -
ceritinib
Laurie, 2014     cediranib carboplatin and paclitaxel -
Goss, 2010     cediranib carboplatin and paclitaxel -
Dy, 2013     cediranib gemcitabine and carboplatin -
docetaxel
REVEL, 2014      NCTramucirumab + docetaxeldocetaxel aloneLow risk of bias -
motesanib
Scagliottib MONET1, 2012     motesanib plus carboplatin/paclitaxel -
pazopanib
Scagliotti, 2013     pazopanib pemetrexed -
sorafenib
Wakelee, 2012     sorafenib -
Paz-Ares, 2012     sorafenib -
Spigel, 2011     sorafenib and erlotinib erlotinib -
Scagliotti, 2010     sorafenibplacebo -
sunitinib
Groen, 2013     sunitinib erlotinib Low risk of bias -
Scagliottia, 2012     Sunitinib plus erlotinib erlotinib -
Heist CALGB 30704 (Alliance): , 2014     sunitinib pemetrexed -
vandetanib
Aisner, 2013     vandetanib -
Ahn, 2013     vandetanib maintenance -
de Boer, 2011     Vandetanib plus pemetrexed -
Natale, 2009     Vandetanib versus gefitinib Low risk of bias -
Natale, 2011     Vandetanib gefitinib Low risk of bias -
Lee ZEPHYR, 2012     Vandetanib placebo -
Heymach, 2007      vandetanib plus docetaxel placebo plus docetaxel -

renal-cell carcinoma (advanced)

bevacizumab
CALGB 90206, 2010         bevacizumab plus interferon alfainterferon alpha -
AVOREN, 2007         bevacizumab plus interferon alfainterferon alpha -
Yang, 2003       bevacizumabplaceboExploratory -